01
Cash & equivalents decreased 47.1%
Cash & equivalents changed -47.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$52.4M→$27.8MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTJanux Therapeutics, Inc.'s latest supported as-filed period reports net income of -$22.0M, 35.1% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -47.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Net income changed +35.1% from the comparable as-filed period.
Operating income changed +29.8% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
JANX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-338078SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193125-26-337977SEC ↗4Jul 31, 2026Period Jul 31, 20260001864158-26-000006SEC ↗4Jul 10, 2026Period Jul 8, 20260001864158-26-000004SEC ↗8-KJun 23, 2026Period Jun 23, 20260001193125-26-279428SEC ↗4Jun 12, 2026Period Jun 11, 20260001231919-26-000631SEC ↗4Jun 12, 2026Period Jun 11, 20260001863094-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 31, 2026Filed Jul 31, 2026 | Campbell David AlanPresident and CEO | GiftDirect | 123,840 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -10.6% from the comparable as-filed period.
Stock-based compensation changed -17.3% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001666963-26-000003